tOPV1,2 & 3LIVE
The live, Oral Poliomyelitis Vaccine (OPV) is a trivalent vaccine containing suspension of types 1, 2 and 3 attenuated poliomyelitis viruses (Sabin strains). Each dose of OPV is indicated for active immunisation of infants, susceptible children and adults against Poliomyelitis caused by polioviruses of Types 1, 2 & 3.
OPV must only be administered orally. Two drops are delivered directly into the mouth from the multi dose vial by dropper.
- Infants should receive at least three doses of OPV at minimum intervals of 4 weeks
- 3 Doses at Birth, 6, 10, 14 weeks are recommended by WHO in endemic countries
- In non-endemic areas the first dose can be given from six weeks with the first dose of DTP.
OPV can be given safely and effectively at the same time as measles, rubella, mumps, DTP, DT, TT, Td, BCG, hepatitis B, Haemophilus influenzae type b, yellow fever vaccine and Vitamin A supplementation.
Booster doses might be considered every second year till the child is about eight years old. Booster doses may also be considered under the threat of an epidemic. It may also be given occasionally in adult life when a person is likely to be exposed to high risk of infection such as persons working or likely to come in contact with the virus and when travelling to endemic areas.
For latest IAP updates see revised immunization schedule.
OPV (Oral Polio Vaccine) trivalent
Haffkine Bio Pharmaceutical Corporation Ltd
No adverse effects are produced by giving OPV to a sick child. In case of diarrhoea or vomiting (including gastro- intestinal infection), the dose received will not be counted as part of the immunization schedule and it should be repeated after recovery.Although there is no evidence that live, attenuated polio vaccines have an adverse effect on the foetus, in accordance with general principles, the vaccine should not be given to pregnant women unless they are exposed to definite risk of infection with wild polioviruses.